A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Ozanimod

Sponsor

Bristol-Myers Squibb